New Wearable Heart Failure Treatment Proves Transformativefor Patients, Major UK Trial Shows

Trial Results Support At-Home Treatment of Edema in Heart Failure with Subcutaneous Furosemide as an Effective and Safe Alternative to Inpatient Hospital Care

BURLINGTON, Mass., May 11, 2026

New wearable heart failure treatment proves transformativefor patients, major UK trial shows

A pioneering heart failure treatment combining a wearable mini-pump and innovative medication can allow patients to leave hospital significantly earlier and safely continue treatment at home, according to results from a major UK clinical trial, led by the University of Glasgow. Findings from the landmark SUBCUT HF II trial were presented at the annual European Society of Cardiology Heart Failure Congress 2026 in Barcelona, on May 9, 2026, demons…

SUBCUT HF II trial reports fewer hospital days for HF patients treated for oedema with novel therapy

Lasix ONYU infusor SQ Innovation has announced topline results from the SUBCUT HF II trial of its product Lasix ONYU, a novel subcutaneous formulation of furosemide for people with heart failure-associated oedema. Patients randomised to treatment at home spent an average of four fewer days in the hospital compared to those treated with standard-of-care intravenous (IV) furosemide, according to the trial’s results, presented at Heart Failure 2026…